ArticleFrontiers in oncology2026

Clinical outcomes of pembrolizumab plus gemcitabine and cisplatin in a Japanese institutional subgroup of KEYNOTE-966: a dexamethasone-minimizing supportive-care approach.

Satoshi Kobayashi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.